Trials are expensive. So are the people that run the company. I'm okay with a little pain now and a good buying opportunity for a vaccine that should be ready to market by EOY '16.
Seems like the market cap would be a more important indicator than an arbitrary number like $5...even after the reverse split the MC is still the same. Are you suggesting that the number 5 makes institutions feel better?
AVNR also sold themselves for a price that many investors believed was too low for the drugs they had. I would hate to see the same thing happen to NVAX. Can you imagine if they settled to be bought out for $14-15, the price it was just a few months back?
This has several levels of support to go through before it even got there. I'm not even sure what you're basing this off of. The Street Sweeper article is just a rehash of their previous short and distort. There is no patent cliff. Consider this, Sid himself said the patents that are expiring in 2017 are for old technology. Any company looking to use those patents to jump into the OLED business will find themselves at a severe disadvantage.
the PR didn't say anything substantive...why even bother with a PR then? they could have at least told us to expect the third party information in a certain time frame but they didn't even do that.